Hepatic insufficiency after portacaval shunting is prevented by prior intraportal pancreatic islet autotransplantation

Mark P. Callery, Camillo Ricordi, David W. Scharp, Takafumi Kamei, Carol J. Swanson, Paul E. Lacy, M. Wayne Flye

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The extrahepatic diversion of essential splanchnic hepatotrophic factors may cause the liver atrophy and insufficiency that follows portacaval shunting. To investigate this, control dogs with end-to-side portacaval shunts (control-PCS, n = 6) were compared with dogs shunted 1 month after intraportal pancreatic islet autotransplantation (islet-Tx-PCS, n = 5). From the distal pancreas of each experimental dog, 1.95 ± 0.49 × 105 islets were isolated by collagenase digestion and retransplanted within 3 hours. Assays of hepatocellular function (caffeine clearance) and hepatic blood flow (indocyanine green), conventional biochemical liver function tests, and glucose, insulin, and glucagon responses to intravenous glucose challenge were measured monthly and when dogs were killed. Four of six control-PCS dogs were killed 32 ± 9 days after shunting because of more than 20% body weight loss; one control-PCS dog lost only 7% of body weight by day 56 and stabilized. No significant loss of body weight occurred in islet- Tx-PCS dogs (n = 5). Liver function test abnormalities seen in control-PCS dogs were absent in islet-Tx-PCS dogs. Both control-PCS and islet-Tx-PCS indocyanine green half-life measurements were significantly (p < 0.05) prolonged at all times, indicating equally reduced hepatic blood flow after shunting for both groups. In contrast, islet- Tx-PCS caffeine half-life periods were significantly (p < 0.05) shorter than in control-PCS dogs and were similar to those in normal dogs, indicating a protective effect of the transplanted islets on hepatocellular function. We conclude that intraportal pancreatic islet autotransplants prevent, by the local release of hepatotrophic factors within the liver, the metabolic abnormalities and loss of hepatic function after PCS.

Original languageEnglish
Pages (from-to)257-266
Number of pages10
JournalSurgery
Volume106
Issue number2
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Hepatic Insufficiency
Autologous Transplantation
Islets of Langerhans
Dogs
Indocyanine Green
Liver
Liver Function Tests
Body Weight
Caffeine
Half-Life
Surgical Portacaval Shunt
Glucose
Viscera
Autografts
Collagenases
Glucagon
Atrophy
Weight Loss
Pancreas
Digestion

ASJC Scopus subject areas

  • Surgery

Cite this

Callery, M. P., Ricordi, C., Scharp, D. W., Kamei, T., Swanson, C. J., Lacy, P. E., & Flye, M. W. (1989). Hepatic insufficiency after portacaval shunting is prevented by prior intraportal pancreatic islet autotransplantation. Surgery, 106(2), 257-266.

Hepatic insufficiency after portacaval shunting is prevented by prior intraportal pancreatic islet autotransplantation. / Callery, Mark P.; Ricordi, Camillo; Scharp, David W.; Kamei, Takafumi; Swanson, Carol J.; Lacy, Paul E.; Flye, M. Wayne.

In: Surgery, Vol. 106, No. 2, 01.01.1989, p. 257-266.

Research output: Contribution to journalArticle

Callery, MP, Ricordi, C, Scharp, DW, Kamei, T, Swanson, CJ, Lacy, PE & Flye, MW 1989, 'Hepatic insufficiency after portacaval shunting is prevented by prior intraportal pancreatic islet autotransplantation', Surgery, vol. 106, no. 2, pp. 257-266.
Callery, Mark P. ; Ricordi, Camillo ; Scharp, David W. ; Kamei, Takafumi ; Swanson, Carol J. ; Lacy, Paul E. ; Flye, M. Wayne. / Hepatic insufficiency after portacaval shunting is prevented by prior intraportal pancreatic islet autotransplantation. In: Surgery. 1989 ; Vol. 106, No. 2. pp. 257-266.
@article{e5ef8e388ac54c078270cc9cc4645a4a,
title = "Hepatic insufficiency after portacaval shunting is prevented by prior intraportal pancreatic islet autotransplantation",
abstract = "The extrahepatic diversion of essential splanchnic hepatotrophic factors may cause the liver atrophy and insufficiency that follows portacaval shunting. To investigate this, control dogs with end-to-side portacaval shunts (control-PCS, n = 6) were compared with dogs shunted 1 month after intraportal pancreatic islet autotransplantation (islet-Tx-PCS, n = 5). From the distal pancreas of each experimental dog, 1.95 ± 0.49 × 105 islets were isolated by collagenase digestion and retransplanted within 3 hours. Assays of hepatocellular function (caffeine clearance) and hepatic blood flow (indocyanine green), conventional biochemical liver function tests, and glucose, insulin, and glucagon responses to intravenous glucose challenge were measured monthly and when dogs were killed. Four of six control-PCS dogs were killed 32 ± 9 days after shunting because of more than 20{\%} body weight loss; one control-PCS dog lost only 7{\%} of body weight by day 56 and stabilized. No significant loss of body weight occurred in islet- Tx-PCS dogs (n = 5). Liver function test abnormalities seen in control-PCS dogs were absent in islet-Tx-PCS dogs. Both control-PCS and islet-Tx-PCS indocyanine green half-life measurements were significantly (p < 0.05) prolonged at all times, indicating equally reduced hepatic blood flow after shunting for both groups. In contrast, islet- Tx-PCS caffeine half-life periods were significantly (p < 0.05) shorter than in control-PCS dogs and were similar to those in normal dogs, indicating a protective effect of the transplanted islets on hepatocellular function. We conclude that intraportal pancreatic islet autotransplants prevent, by the local release of hepatotrophic factors within the liver, the metabolic abnormalities and loss of hepatic function after PCS.",
author = "Callery, {Mark P.} and Camillo Ricordi and Scharp, {David W.} and Takafumi Kamei and Swanson, {Carol J.} and Lacy, {Paul E.} and Flye, {M. Wayne}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "106",
pages = "257--266",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Hepatic insufficiency after portacaval shunting is prevented by prior intraportal pancreatic islet autotransplantation

AU - Callery, Mark P.

AU - Ricordi, Camillo

AU - Scharp, David W.

AU - Kamei, Takafumi

AU - Swanson, Carol J.

AU - Lacy, Paul E.

AU - Flye, M. Wayne

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The extrahepatic diversion of essential splanchnic hepatotrophic factors may cause the liver atrophy and insufficiency that follows portacaval shunting. To investigate this, control dogs with end-to-side portacaval shunts (control-PCS, n = 6) were compared with dogs shunted 1 month after intraportal pancreatic islet autotransplantation (islet-Tx-PCS, n = 5). From the distal pancreas of each experimental dog, 1.95 ± 0.49 × 105 islets were isolated by collagenase digestion and retransplanted within 3 hours. Assays of hepatocellular function (caffeine clearance) and hepatic blood flow (indocyanine green), conventional biochemical liver function tests, and glucose, insulin, and glucagon responses to intravenous glucose challenge were measured monthly and when dogs were killed. Four of six control-PCS dogs were killed 32 ± 9 days after shunting because of more than 20% body weight loss; one control-PCS dog lost only 7% of body weight by day 56 and stabilized. No significant loss of body weight occurred in islet- Tx-PCS dogs (n = 5). Liver function test abnormalities seen in control-PCS dogs were absent in islet-Tx-PCS dogs. Both control-PCS and islet-Tx-PCS indocyanine green half-life measurements were significantly (p < 0.05) prolonged at all times, indicating equally reduced hepatic blood flow after shunting for both groups. In contrast, islet- Tx-PCS caffeine half-life periods were significantly (p < 0.05) shorter than in control-PCS dogs and were similar to those in normal dogs, indicating a protective effect of the transplanted islets on hepatocellular function. We conclude that intraportal pancreatic islet autotransplants prevent, by the local release of hepatotrophic factors within the liver, the metabolic abnormalities and loss of hepatic function after PCS.

AB - The extrahepatic diversion of essential splanchnic hepatotrophic factors may cause the liver atrophy and insufficiency that follows portacaval shunting. To investigate this, control dogs with end-to-side portacaval shunts (control-PCS, n = 6) were compared with dogs shunted 1 month after intraportal pancreatic islet autotransplantation (islet-Tx-PCS, n = 5). From the distal pancreas of each experimental dog, 1.95 ± 0.49 × 105 islets were isolated by collagenase digestion and retransplanted within 3 hours. Assays of hepatocellular function (caffeine clearance) and hepatic blood flow (indocyanine green), conventional biochemical liver function tests, and glucose, insulin, and glucagon responses to intravenous glucose challenge were measured monthly and when dogs were killed. Four of six control-PCS dogs were killed 32 ± 9 days after shunting because of more than 20% body weight loss; one control-PCS dog lost only 7% of body weight by day 56 and stabilized. No significant loss of body weight occurred in islet- Tx-PCS dogs (n = 5). Liver function test abnormalities seen in control-PCS dogs were absent in islet-Tx-PCS dogs. Both control-PCS and islet-Tx-PCS indocyanine green half-life measurements were significantly (p < 0.05) prolonged at all times, indicating equally reduced hepatic blood flow after shunting for both groups. In contrast, islet- Tx-PCS caffeine half-life periods were significantly (p < 0.05) shorter than in control-PCS dogs and were similar to those in normal dogs, indicating a protective effect of the transplanted islets on hepatocellular function. We conclude that intraportal pancreatic islet autotransplants prevent, by the local release of hepatotrophic factors within the liver, the metabolic abnormalities and loss of hepatic function after PCS.

UR - http://www.scopus.com/inward/record.url?scp=0024439049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024439049&partnerID=8YFLogxK

M3 - Article

C2 - 2503900

AN - SCOPUS:0024439049

VL - 106

SP - 257

EP - 266

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 2

ER -